Welcome to our dedicated page for Point Biopharma Global news (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on Point Biopharma Global stock.
POINT Biopharma Global Inc. (PNT) delivers targeted radiopharmaceutical therapies for cancer treatment, with its pending acquisition by Eli Lilly marking a significant evolution in precision oncology. This page provides essential updates on clinical developments, regulatory milestones, and corporate strategy for investors tracking PNT's innovative radioligand pipeline.
Access timely announcements about 177Lu-PNT2002 clinical progress, manufacturing expansions, and partnership developments. Our curated news collection features earnings reports, trial data publications, and acquisition-related disclosures – all critical for understanding PNT's position in the evolving radiopharmaceutical sector.
Key updates include the Phase 3 SPLASH study outcomes for metastatic prostate cancer treatment and strategic moves following the $1.4 billion acquisition agreement. Bookmark this page for streamlined access to verified financial filings, therapy approval timelines, and material event disclosures that shape PNT's growth trajectory.
Eckert & Ziegler and POINT Biopharma have signed a supply agreement for Actinium-225 (Ac-225), a radioisotope used in cancer treatment. The partnership aims to support the development of POINT's pipeline of Ac-225-based radioligands. Ac-225 is expected to see increasing demand due to its ability to precisely target tumor cells while minimizing damage to healthy tissue. Eckert & Ziegler plans to enhance production capabilities to meet market needs. POINT Biopharma is focusing on ongoing research and plans to launch its first Ac-225 phase 1 trial for the PNT2001 program later in 2023.
POINT Biopharma Global Inc. (PNT) announced a strategic collaboration with Lantheus Holdings for its PNT2002 and PNT2003 product candidates, bolstered by a $260 million upfront payment. The company's cash reserves exceed $541 million, expected to fund operations into 2026. Enrollment for the phase 3 SPLASH trial of PNT2002 is complete, with top-line data anticipated in H2 2023. In 2022, POINT reported a net income of $98.3 million, a turnaround from a $45.9 million loss in 2021, while R&D expenses surged to $82.1 million. The company aims to enhance its manufacturing capabilities with new production lines expected by year-end.
POINT Biopharma Global Inc. (NASDAQ: PNT) has confirmed that its SPLASH clinical trial for the PSMA-targeted PNT2002 program is on schedule without any manufacturing or supply chain disruptions. CEO Joe McCann highlighted the company's strategic investments in supply chain and manufacturing to enhance patient access to radioligand therapies. The in-house production of no-carrier-added 177Lu is expected to start by the end of 2023, reinforcing POINT’s commitment to resiliency in the radiopharmaceutical supply chain. Additionally, POINT is progressing with clinical trials, including the phase 1 FRONTIER trial for PNT2004, targeting cancer treatment.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced participation in several upcoming investor conferences. Notable events include the Guggenheim 5th Annual Oncology Conference in New York on February 8, 2023, and the SVB Securities Global Biopharma Conference virtually on February 16, 2023. Other conferences include the Cowen Healthcare Conference in Boston on March 7, 2023, Oppenheimer Healthcare Investor Conference virtually on March 13, 2023, and the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 25-26, 2023. The company focuses on developing radiopharmaceuticals for cancer treatment and has active clinical trials for its product candidates PNT2004 and PNT2002.
POINT Biopharma Global Inc. has completed enrollment for the randomization phase of the pivotal phase 3 SPLASH trial, meeting its timeline goals. This trial investigates PNT2002 for patients with PSMA-expressing metastatic castration-resistant prostate cancer who have progressed on other therapies. Over 390 participants were enrolled across 55 sites in North America, Europe, and the UK. In partnership with Lantheus Holdings Inc., POINT will fund the SPLASH trial and collaborate on regulatory filings. The primary endpoint is radiographic progression-free survival, with key secondary endpoints including overall response rate and overall survival.
POINT Biopharma Global Inc. (NASDAQ: PNT) has confirmed that closing conditions for its agreements with Lantheus Holdings Inc. have been met, allowing POINT to receive $260 million upfront next week. Future potential payments include up to $250 million for PNT2002 and up to $30 million for PNT2003 upon FDA approval, in addition to milestone payments and royalties. POINT plans to use these funds to enhance its radioligand platform and expects to fund operations into 2026 while advancing multiple clinical trials.
POINT Biopharma Global Inc. (PNT) reported promising preclinical findings on its lead candidate, 177Lu-PNT6555, which demonstrated significant survival benefits when combined with anti-PD-1 immunotherapy in a resistant tumor model. This candidate is part of the PNT2004 program, currently in phase 1 trials. The study suggests potential for enhanced efficacy in cancer treatment, particularly for tumors resistant to existing therapies. POINT aims to expand its clinical trials and improve patient access to radiopharmaceuticals, capitalizing on opportunities in various cancer indications.
POINT Biopharma Global Inc. (NASDAQ: PNT) reported Q3 2022 financial results, revealing a net loss of $24 million, or $0.26 per share. This compares to a net loss of $17.1 million, or $0.19 per share, in Q3 2021. The company announced a strategic collaboration with Lantheus Holdings Inc. for PNT2002 and PNT2003, totaling $260 million in upfront payments and potential milestone payments of $1.8 billion. POINT holds $291.5 million in cash, projected to fund operations into Q4 2024, while R&D expenses rose to $20.8 million, reflecting ongoing development efforts.
Lantheus and POINT Biopharma have entered a collaboration to license the exclusive worldwide rights for two late-stage therapeutic agents, PNT2002 and PNT2003. Lantheus will pay $260 million in upfront payments and has the potential for an additional $1.8 billion in milestone payments based on FDA approvals and sales. POINT will continue to advance its clinical trials while Lantheus prepares for commercialization. This partnership is expected to drive revenue growth for Lantheus and provide POINT with the resources necessary to focus on its pipeline, reducing the need for dilutive fundraising.
POINT Biopharma Global Inc. announced promising pre-clinical results for PNT2001, a next-generation radioligand therapy for prostate cancer, exhibiting enhanced internalization and biodistribution. The data, shared at the European Association of Nuclear Medicine Congress, showcases effective tumor targeting and safety in murine models. POINT aims for an IND submission for PNT2001 in H1 2023. Concurrently, the company is preparing for the SPLASH trial, evaluating PNT2002 in prostate cancer patients not eligible for chemotherapy.
FAQ
What is the market cap of Point Biopharma Global (PNT)?
